ANRS 149 Light

Status:Completed
Phase:II
Principal Investigator(s):Yves Lévy, PU-PH
Objective:The combination of GTU-MultiHIV B DNA and LIPO-5 vaccines in a prime-boost strategy is expected to induce strong and diverse HIV-specific immune responses in HIV-infected patients. The investigators will carry out the clinical therapeutic immunization "proof of concept" trial in HIV infected patients. Last updated March 24, 2021
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionVaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
Mode of DeliveryBiojector
ARMsExperimental
Results: A randomized placebo-controlled efficacy study of a prime boost therapeutic vaccination strategy in HIV-1 infected individuals: VRI02 ANRS 149 LIGHT Phase II trial
Official Code: NCT01492985
Related Publications:
Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect
Trial Sponsors: Inserm-ANRS
Start Date
End Date
July 1, 2013
April 8, 2017
Enrollment:103
Age range: 18 Years ↔ 59 Years
Population:Cisgender Men, Cisgender Women, People Living with HIV